Tate & Lyle Acquisition Moves Forward: Shareholder Approval Secured
Tate & Lyle shareholders have approved Ingredion's £2.7 billion all-cash offer, advancing the creation of a unified speciality ingredient powerhouse. Completion is contingent on antitrust clearances and court sanction, anticipated by H2 2027.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 29 July 2026
Tate & Lyle shareholders have formally approved Ingredion’s recommended all-cash acquisition valuing the company at £2.7 billion. At a court-convened meeting on 28 July, 82.03% of voting shareholders supported the scheme of arrangement, representing 98.64% of votes cast. A separate general meeting also saw 98.64% approval for the resolution to implement the transaction. This marks a significant step towards creating a consolidated speciality ingredients group.
Despite shareholder consensus, the acquisition remains subject to critical antitrust clearances, a UK High Court sanction, and formal registration with the Registrar of Companies. The deal is projected to close in the second half of 2027. Until then, both Ingredion and Tate & Lyle will continue independent operations. Ingredion chairman, president, and CEO Jim Zallie highlighted this approval as a crucial landmark in establishing a global leader in ingredient solutions, as reported by Food Ingredients First.
The strategic rationale for this merger focuses on combining complementary ingredient portfolios and technical expertise. Ingredion offers strengths in starches, clean-label texturizers, and plant-based solutions, while Tate & Lyle brings advanced capabilities in mouthfeel, sweetening, and fortification, bolstered by its 2024 acquisition of CP Kelco. The combined entity is expected to achieve US$9.9 billion in revenue and US$1.8 billion in adjusted EBITDA, according to earlier reports from Food Ingredients First.
Supplement manufacturers and brand owners can expect an enhanced offering of ingredients designed to meet complex product development demands, including sugar reduction, texture optimisation, and nutrient fortification. The combined innovation network and expanded geographic footprint are intended to improve ingredient supply reliability and cost-effectiveness. Ingredion forecasts approximately US$130 million in annual run-rate net cost synergies by the end of 2030, derived from procurement, logistics, and operational efficiencies.
What this means for United Kingdom
UK-based supplement manufacturers need to reassess their ingredient supply chain strategies. This consolidation could lead to fewer, larger ingredient suppliers, potentially impacting negotiating power for smaller brands. Reformulation windows for existing products may tighten as new ingredient solutions become available, urging brands to explore opportunities for enhanced product profiles in sugar reduction or advanced texture. Procurement teams should engage with both Ingredion and Tate & Lyle to understand future product roadmaps, lead times, and MOQ changes. Compliance teams must monitor any potential changes to ingredient specifications or documentation that might arise from integration, ensuring continued adherence to FSA and MHRA guidelines for product composition and claims. Competitive positioning will shift, favouring brands that can leverage these advanced ingredient portfolios for novel product development.
The acquisition also reflects Ingredion's broader strategy to divest from commodity-linked assets, evidenced by its US$165 million sale of a 51% stake in Pakistan-based Rafhan Maize, while retaining 20% interest. This move sharpens Ingredion's focus on higher-growth, value-added speciality ingredients, which could lead to increased investment in R&D for functional applications relevant to the supplement sector.
Many leading brands in this category are manufactured in partnership with Supplement Factory.